/ Unknown statusNot Applicable A Phase I, Multicentre, Open-label, Self-control Study to Evaluate the Pharmacokinetics of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A
Primary objective: To assess the pharmacokinetics of Recombinant Human Coagulation Factor VIII-Fc fusion protein for Injection at two dose levels in patients with hemophilia A.
Secondary objectives: To assess Safety and Tolerability by monitoring FVIII recovery and adverse events in patients with hemophilia A.
A Phase I, Multicentre, Open-Label, Self-control Study for Evaluation of the Pharmacokinetics, Safety and Tolerability of Recombinant Human Coagulation Factor VIII-Fc fusion protein for Injection in Adolescent and Adult Patients With Hemophilia A
100 Clinical Results associated with Beijing Furen Ruihui Biomedical Research Institute Co., Ltd.
0 Patents (Medical) associated with Beijing Furen Ruihui Biomedical Research Institute Co., Ltd.
100 Deals associated with Beijing Furen Ruihui Biomedical Research Institute Co., Ltd.
100 Translational Medicine associated with Beijing Furen Ruihui Biomedical Research Institute Co., Ltd.